{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-142119","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.218172+00:00","generated_at":"2026-06-15T03:39:12.418605+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MEI Pharma Q3 net loss $15.4M; cash $112M; Kyowa Kirin ends zandelisib; merger with Infinity pending","bullets":["Net loss $15.4M ($2.32/share) in Q3 FY2023 vs $8.7M loss ($1.31/share) in Q3 FY2022.","Revenue fell to $5.9M from $9.7M due to zandelisib program discontinuation and reduced Kyowa Kirin reimbursements.","Kyowa Kirin ended zandelisib development in Japan; parties will terminate global license agreement.","Executed 1-for-20 reverse stock split in April 2023; regained Nasdaq minimum bid compliance as of May 2, 2023.","Pending all-stock merger with Infinity Pharmaceuticals; combined cash ~$100M expected to fund operations through mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-142119","json":"https://secwatch.observer/filing/0001193125-23-142119.json","markdown":"https://secwatch.observer/filing/0001193125-23-142119.md","text":"https://secwatch.observer/filing/0001193125-23-142119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523142119/0001193125-23-142119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523142119/d509683d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:39:12.418605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e5e89b0294d6d332d605909d8f683e3a17e73dd","claim":"Lite Strategy, Inc. reported the quarter ended March 31, 2023 results: revenue $5.9 million, net income Net loss was $15.4 million, or $2.32 per share, EPS $2.32 per share.","evidence_excerpt":"to $8.9 million for the quarter ended March 31, 2022. The decrease primarily relates to personnel costs related to the reduction in workforce. • MEI recognized revenue of $5.9 million for the quarter ended March 31, 2023, compared to $9.7 million for the quarter ended March 31, 2022. The decrease in revenue comes as a result of the discontinuation of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523142119/0001193125-23-142119-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$5.9 million"},{"label":"Net income","value":"Net loss was $15.4 million, or $2.32 per share"},{"label":"EPS","value":"$2.32 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}